HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Metyrapone

An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.

Also Known As:

Alliance Brand of Metyrapone; Metopiron; Metopirone; Métopirone; Novartis Brand of Metyrapone; SU 4885; 4885, SU; Metyrapone Alliance Brand; Metyrapone Novartis Brand; Methbipyranone; Methopyrapone; 1-Propanone, 2-methyl-1,2-di-3-pyridinyl-

Networked: 505 relevant articles (29 outcomes, 42 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Pyridines: 41
    - Metyrapone: 505

Experts

1.	Otte, Christian: 5 articles (04/2007 - 09/2003)
2.	Neylan, Thomas C: 4 articles (09/2014 - 09/2003)
3.	Tufik, Sergio: 4 articles (05/2013 - 04/2008)
4.	Yehuda, Rachel: 4 articles (10/2009 - 09/2003)
5.	Guerin, Glenn F: 3 articles (09/2014 - 01/2014)
6.	Goeders, Nicholas E: 3 articles (09/2014 - 01/2014)
7.	Schmoutz, Christopher D: 3 articles (09/2014 - 01/2014)
8.	Marek, J: 3 articles (07/2010 - 02/2001)
9.	Marmar, Charles R: 3 articles (04/2007 - 09/2003)
10.	Yassouridis, Alexander: 3 articles (10/2006 - 08/2004)

Related Diseases

1.	Cushing Syndrome 02/01/2001 - "Metyrapone suppression of hypercortisolism currently represents the best treatment for these rare cases." 09/01/1993 - "Metyrapone therapy is effective in controlling the hypercortisolism in certain cases of Cushing's syndrome complicating pregnancy." 05/01/1981 - "Prolonged remission in florid Cushing's syndrome following metyrapone treatment." 11/01/2015 - "Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients." 01/01/2015 - "The baby girl underwent medical treatment of Cushing's syndrome with metyrapone which was followed by a rapid recovery. "
2.	Post-Traumatic Stress Disorders (PTSD) 09/01/2003 - "Metyrapone caused an increase in awakenings and a marked decrease in quantitative measures of delta sleep that was significantly greater in controls compared to PTSD. " 07/01/2006 - "We present data from several studies examining the effect of metyrapone administration on the sleep EEG in PTSD and control subjects. " 08/01/2004 - "Dose-response studies using metyrapone and glucocorticoid agonists are needed to further investigate HPA axis regulation in PTSD." 09/01/2014 - "Sex differences in neurosteroid and hormonal responses to metyrapone in posttraumatic stress disorder." 10/01/2009 - "The metyrapone stimulation test was performed to further characterize hypothalamic-pituitary activity in Gulf War veterans (GWV) and its relationship to unexplained medical symptoms and post-traumatic stress disorder (PTSD). "
3.	Pituitary Diseases (Disease, Anterior Pituitary) 03/01/1969 - "Studies of metyrapone responses in patients with pituitary disease." 01/01/2003 - "Abnormal responses should be considered diagnostic, while normal responses, especially in newly onset or recent pituitary disease, should be followed by either ITT or metyrapone test. " 08/01/2000 - "The overnight metyrapone test was performed only in the subjects with pituitary disease. " 11/01/1964 - "METHOPYRAPONE TESTS IN HYPOTHALAMIC-PITUITARY DISEASE." 08/01/2000 - "The 65 patients with pituitary disease were categorized according to the 11-deoxycortisol response to metyrapone as follows: 53 normal (11-deoxycortisol > 200 nmol/l) and 12 subnormal (< 200 nmol/l). "
4.	Seizures (Seizure) 07/01/2011 - "Here we demonstrate that metyrapone affords dose-dependent protection against 6-Hz seizures 30 min after injection (ED(50), 191 mg/kg), but is markedly more potent at 6 h (ED(50), 30 mg/kg). " 01/01/1998 - "How does metyrapone decrease seizures?" 07/01/1996 - "Seizure-induced damage to hippocampal pyramidal neurons (assessed by cell counts and immunochemical analyses of cytoskeletal alterations) was significantly reduced in rats administered metyrapone. " 11/08/1988 - "Thus, metyrapone, which is used safely and efficaciously in other clinical contexts, might prove protective of the brain following seizure in the human." 11/08/1988 - "Metyrapone did not change the intensity of seizures, but rather, apparently, changed the capacity of neurons to withstand the seizure. "
5.	Ischemia 12/01/2012 - "However, metyrapone injection did not influence the protective effect of CRF on the gastric mucosa against ischemia-reperfusion-induced lesion. " 06/04/1999 - "Transient forebrain ischemia was induced in gerbils, and the effect of a pre-ischemic treatment with metyrapone (100 mg/kg) on delayed neuronal death in hippocampal CA1 neurons was evaluated. " 04/01/2011 - "The single dose of metyrapone attenuated the ischemia-induced adrenocortical hyper-responsiveness and subsequent memory deficits despite not providing neuroprotection in the hippocampal CA1 pyramidal cells. " 10/01/1999 - "Metyrapone, but none of the other compounds, attenuated the occurrence of seizures immediately after ischemia. " 06/04/1999 - "The metyrapone treatment morphologically improved the damage provoked by 3 min of ischemia, although it did not alleviate the damage by 5 min. Ischemia for 3 min produced a 306% increase in the glutamate concentration in perfusates, and metyrapone suppressed the peak value to 42% of that in the control group. "

Related Drugs and Biologics

1.	Adrenocorticotropic Hormone (ACTH)
2.	Aminoglutethimide (Cytadren)
3.	Steroid 11-beta-Hydroxylase (11 beta-Hydroxylase)
4.	Dexamethasone (Maxidex)
5.	Corticosterone
6.	Ketoconazole (Nizoral)
7.	Mitotane (Lysodren)
8.	Insulin (Novolin)
9.	Mifepristone (RU 486)
10.	Hydrocortisone (Cortisol)

Related Therapies and Procedures

1.	Radiotherapy
2.	Drug Therapy (Chemotherapy)
3.	Liver Transplantation
4.	Adrenalectomy
5.	Injections